A detailed history of Principal Financial Group Inc transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 27,880 shares of OCUL stock, worth $190,699. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,880
Previous 21,959 26.96%
Holding current value
$190,699
Previous $97,000 160.82%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$3.85 - $10.93 $22,795 - $64,716
5,921 Added 26.96%
27,880 $253,000
Q4 2023

Feb 07, 2024

SELL
$2.08 - $4.52 $232 - $506
-112 Reduced 0.51%
21,959 $97,000
Q3 2023

Nov 02, 2023

SELL
$3.14 - $5.04 $549 - $882
-175 Reduced 0.79%
22,071 $69,000
Q2 2023

Aug 07, 2023

SELL
$4.6 - $7.64 $2,875 - $4,775
-625 Reduced 2.73%
22,246 $114,000
Q1 2023

May 09, 2023

SELL
$2.79 - $6.27 $4,729 - $10,627
-1,695 Reduced 6.9%
22,871 $120,000
Q4 2022

Feb 09, 2023

BUY
$2.61 - $4.41 $11,669 - $19,717
4,471 Added 22.25%
24,566 $69,000
Q3 2022

Nov 09, 2022

SELL
$4.09 - $6.5 $1,946 - $3,094
-476 Reduced 2.31%
20,095 $84,000
Q2 2022

Aug 10, 2022

BUY
$3.01 - $5.22 $19,673 - $34,117
6,536 Added 46.57%
20,571 $83,000
Q1 2022

May 09, 2022

BUY
$4.83 - $7.35 $4,825 - $7,342
999 Added 7.66%
14,035 $69,000
Q4 2021

Feb 09, 2022

SELL
$6.16 - $12.07 $817,462 - $1.6 Million
-132,705 Reduced 91.06%
13,036 $91,000
Q3 2021

Nov 09, 2021

BUY
$9.7 - $14.34 $5,247 - $7,757
541 Added 0.37%
145,741 $1.46 Million
Q2 2021

Aug 10, 2021

BUY
$13.43 - $19.16 $1.55 Million - $2.22 Million
115,671 Added 391.72%
145,200 $2.06 Million
Q1 2021

May 10, 2021

SELL
$15.82 - $22.11 $13,225 - $18,483
-836 Reduced 2.75%
29,529 $484,000
Q4 2020

Feb 08, 2021

BUY
$7.91 - $22.95 $240,187 - $696,876
30,365 New
30,365 $628,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $526M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.